New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Skye Bioscience, Inc.

Contributing Author

Recent Articles by Skye Bioscience, Inc.

Oct-06	Skye Bioscience Reports Topline CBeyond Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial SKYE GlobeNewswire
Sep-19	Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting SKYE GlobeNewswire
Sep-04	Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model SKYE GlobeNewswire
Sep-02	Skye Completes 26-week Treatment Phase in Phase 2a CBeyond Study SKYE GlobeNewswire
Aug-27	Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond Phase 2a Topline Clinical Data Readout SKYE GlobeNewswire
Aug-21	Skye Bioscience to Participate in Upcoming Investment and Medical Conferences SKYE GlobeNewswire
Aug-07	Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update SKYE GlobeNewswire
Jul-30	Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025 SKYE GlobeNewswire
Jun-23	Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions SKYE GlobeNewswire
Jun-17	Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions SKYE GlobeNewswire
May-22	Skye Bioscience to Participate in Upcoming Investment Conferences SKYE GlobeNewswire
May-19	Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab SKYE GlobeNewswire
May-13	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SKYE GlobeNewswire
May-13	Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity SKYE GlobeNewswire
May-08	Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity SKYE GlobeNewswire
May-07	Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 SKYE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.